In conclusion, the discovery of MUC21 as a negative marker for mesothelioma and lung adenocarcinoma represents a significant advancement in the field of cancer research and holds promise for improving patient outcomes in the future. This evidence concerns the gene MUC21 and lung adenocarcinoma.